Last reviewed · How we verify
Saw Palmetto - first 24 weeks
Saw palmetto may inhibit the conversion of testosterone to dihydrotestosterone (DHT), a hormone involved in hair loss and prostate issues.
Saw palmetto may inhibit the conversion of testosterone to dihydrotestosterone (DHT), a hormone involved in hair loss and prostate issues. Used for Benign prostatic hyperplasia (BPH), Androgenetic alopecia.
At a glance
| Generic name | Saw Palmetto - first 24 weeks |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Phytotherapeutic |
| Target | 5-alpha-reductase |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of saw palmetto's effects on hair loss and prostate issues is not fully understood, but it is thought to involve the inhibition of 5-alpha-reductase, an enzyme that converts testosterone to DHT. This may lead to a decrease in DHT levels, which in turn may slow or stop hair loss and alleviate prostate issues.
Approved indications
- Benign prostatic hyperplasia (BPH)
- Androgenetic alopecia
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saw Palmetto - first 24 weeks CI brief — competitive landscape report
- Saw Palmetto - first 24 weeks updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI